XML 71 R39.htm IDEA: XBRL DOCUMENT

Collaborative and Other Relationships (Tables)

6 Months Ended

Jun. 30, 2021

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Summary of Activity Related to BAN2401 and Elenbecestat Collaboration


						For the Three Months Ended June 30,												For the Six Months Ended June 30,
(In millions)						2021						2020						2021						2020
Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat						$	62.2					$	33.9					$	117.7					$	77.5
Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income						31.1						17.0						58.8						38.7
Total sales and marketing expense incurred by the Lecanemab Collaboration						4.3						1.4						10.0						6.3
Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income						2.1						0.7						5.0						3.2

Summary of Activity Related to Aducanumab Collaboration

A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:


						For the Three Months Ended June 30,												For the Six Months Ended June 30,
(In millions)						2021						2020						2021						2020
Total ADUHELM development expense						$	42.1					$	35.9					$	89.1					$	55.0
Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income						23.2						19.7						49.0						30.3
Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement						125.6						45.2						237.4						67.9
Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing in our condensed consolidated statements of income						67.6						25.2						127.9						37.5
Total ADUHELM collaboration third party milestones						100.0						75.0						100.0						75.0
Biogen's share of reimbursement from Eisai of ADUHELM milestone payments reflected in collaboration profit sharing in our condensed consolidated statements of income						45.0						33.8						45.0						33.8

Summary of Activity Related to Denali Therapeutics Collaboration

A summary of development expense related to this collaboration is as follows:


						For the Three Months Ended June 30,												For the Six Months Ended June 30,
(In millions)						2021						2020						2021						2020
Total Denali collaboration development expense						$	10.4					$	—					$	18.7					$	—
Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income						6.2						—						11.2						—